We are live on ! Find out more
SNTI icon

Senti Biosciences Holdings

23 hedge funds and large institutions have $27.8M invested in Senti Biosciences Holdings in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 2

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

5% more funds holding

Funds holding: 22 → 23 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1.62% less ownership

Funds ownership: 32.4% → 30.78% (-1.6%)

49% less capital inflows, than outflows

Capital inflows: $1.69M | Capital outflows: $3.34M

Holders
23
Holders Change
+1
Holders Change %
+4.55%
% of All Funds
0.39%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
8
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

SNTI Hedge Fund Activity: Q3 2022 in Review

23 of the 5,834 institutional investors tracked by Wall St. Rank reported a position in Senti Biosciences Holdings (SNTI) for Q3 2022, worth a combined $27.8M — down 37% from $44.4M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new SNTI positions and 5 closed out — a net gain of 1 holder — while 8 added to existing stakes and 2 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $839K. The largest seller was CAAS Capital Management, exiting entirely with an estimated $1.49M sold.

  • 23 institutional investors held Senti Biosciences Holdings (SNTI) as of Q3 2022, up from 22 in Q2 2022.
  • Funds reported $27.8M of Senti Biosciences Holdings stock for Q3 2022, down 37% quarter-over-quarter.
  • 6 funds opened new Senti Biosciences Holdings positions in Q3 2022 and 5 closed out, a net change of +1 holder.
  • The largest Senti Biosciences Holdings buyer in Q3 2022 was T. Rowe Price Associates, an estimated $839K added.
  • The largest Senti Biosciences Holdings seller in Q3 2022 was CAAS Capital Management, an estimated $1.49M sold.

Based on aggregated 13F filings for Q3 2022.